Perfecting breast-cancer treatment - Incremental gains and musculoskeletal pains

New England Journal of Medicine

Volumn 372, Issue 5, 2015, Pages 477-478

  Hershman, Dawn L ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; EXEMESTANE; TAMOXIFEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; TRIPTORELIN;

BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; EDITORIAL; HUMAN; MONOTHERAPY; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; MUSCULOSKELETAL STIFFNESS; OSTEOPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT OUTCOME; BREAST NEOPLASMS; FEMALE;

ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; TAMOXIFEN; TRIPTORELIN PAMOATE;

EID: 84921848224     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1413164     Document Type: Editorial

References (11)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
2. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11: 1135-41.
3. Goss PE, Ingle JN, Martino S, et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 2007; 25: 2006-11.
4. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-16.
5. Erratum, Lancet 2013; 381: 804.
6. Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372: 436-46.
7. Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371: 107-18.
8. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8, 769 early-stage breast cancer patients. J Clin Oncol 2010; 28: 4120-8.
9. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007; 25: 3877-83.
10. Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013; 14: 1067-76.
11. Sgroi DC, Carney E, Zarrella E, et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst 2013; 105: 1036-42.